2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
1
Active Trials
146 recruiting
3
Rare Diseases
across 6 areas
0
News (30d)
Quiet
Mabwell (Shanghai) Bioscience Co., Ltd. is a company with 2 orphan drug designations across 3 rare diseases. Active clinical trials in 1 indication.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| esophageal cancer | Anti-nectin-4 IgG1 monoclonal antibody conjugated to monomethyl auristatin E | Des.TrialAppr. |
| small cell lung carcinoma | Antibody drug conjugate consisting of a B7-H3-directed monoclonal antibody conjugated to MF-6 | Des.TrialAppr. |
| thalassemia | - | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
8
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
8
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio